(Reuters) – An initial leukemia drug from Ariad Pharmaceuticals Inc separated a cancer from a bone pith of scarcely half of patients with a ongoing form of a illness who had stopped responding to other drugs, according to a 12-month follow-up of a pivotal drug trial.
The hearing of a drug, ponatinib, that concerned 444 patients, including 267 with ongoing myeloid leukemia who had formerly been treated with comparison drugs, also showed that 56 percent of ongoing patients achieved a study’s idea of a “major response,” definition a illness had scarcely left from a bone marrow.
Ariad
Read full article: http://online.wsj.com/article/SB10001424127887324894104578109000926531558.html
Source:
http://www.ezonearticle.com/2012/12/09/ariad-drug-proves-effective-in-curbing-chronic-leukemia-in-study/
0 comments:
Post a Comment